Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study

被引：0

作者：

Lordick, F. ^{[1
,2
]}

Shitara, K. ^{[3
]}

Bang, Y. -J ^{[4
]}

Enzinger, P. ^{[5
]}

Ilson, D. ^{[6
]}

Shah, M. A. ^{[7
]}

Van Cutsem, E. ^{[8
,9
]}

Xu, R. -H ^{[10
]}

Aprile, G. ^{[11
]}

Xu, J. ^{[12
]}

Chao, J. ^{[13
]}

Pazo-Cid, R. ^{[14
]}

Kang, Y. K. ^{[15
]}

Yang, J. ^{[16
]}

Moran, D. ^{[16
]}

Bhattacharya, P. ^{[16
]}

Arozullah, A. ^{[16
]}

Park, J. W. ^{[16
]}

Ajani, J. ^{[17
]}

机构：

[1] Univ Leipzig, Med Ctr, Dept Med, Leipzig, Germany

[2] Univ Canc Ctr Leipzig, Leipzig, Germany

[3] Natl Canc Ctr Hosp East, Kashiwa, Japan

[4] Seoul Natl Univ, Coll Med, Seoul, South Korea

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[9] Katholieke Univ Leuven, Leuven, Belgium

[10] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[11] Azienda ULSS 8 Berica, Vicenza, Italy

[12] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[13] City Hope Comprehens Canc Ctr, Duarte, CA USA

[14] Hosp Univ Miguel Servet, Zaragoza, Spain

[15] Asan Med Ctr, Seoul, South Korea

[16] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V841

引用

页码：115 / 116

页数：2

共 50 条

[1] Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From GLOW
Lordick, F.
Xu, R. -H
Shitara, K.
Ajani, J. A.
Bang, Y. -J
Enzinger, P.
Ilson, D.
Van Cutsem, E.
Gallego Plazas, J.
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Hoo, Soo H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Arozullah, A.
Shah, M. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 116 - 117
[2] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Shitara, Kohei
Lordick, Florian
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Shah, Manish A.
Van Cutsem, Eric
Xu, Rui-hua
Aprile, Giuseppe
Xu, Jianming
Chao, Joseph
Pazo-Cid, Roberto
Kang, Yoon-Koo
Yang, Jianning
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Park, Jung Wook
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292
[3] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
Xu, Rui-Hua
Shitara, Kohei
Ajani, Jaffer A.
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Lordick, Florian
Van Cutsem, Eric
Gallego Plazas, Javier
Huang, Jing
Shen, Lin
Oh, Sang Cheul
Sunpaweravong, Patrapim
Soo Hoo, Hwoei Fen
Turk, Haci M.
Park, Jung Wook
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 405736 - 405736
[4] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER22locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
Xu, Rui-hua
Shitara, Kohei
Ajani, Jaffer A.
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Lordick, Florian
Van Cutsem, Eric
Plazas, Javier Gallego
Huang, Jing
Shen, Lin
Oh, Sang Cheul
Sunpaweravong, Patrapim
Hoo, Hwoei Fen Soo
Turk, Haci M.
Park, Jung Wook
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[5] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Ajani, J. A.
Lordick, F.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
Shah, M. A.
van Cutsem, E.
Xu, R-H.
Aprile, G.
Xu, J.
Pazo Cid, R. A.
Kang, Y-K.
Yang, J.
Moran, D.
Bhattacharya, P.
Matsangou, M.
Arozullah, A.
Park, J. W.
Shitara, K.
ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525
[6] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Shitara, Kohei
Van Cutsem, Eric
Lordick, Florian
Enzinger, Peter C.
Ilson, David H.
Shah, Manish A.
Xu, Rui-Hua
Lonardi, Sara
Yamaguchi, Kensei
Hung, Yi-Ping
Kukielka-Budny, Bozena
Bhattacharya, Pranob P.
Matsangou, Maria
Li, Ran
Moran, Diarmuid Martin
Ranganath, Radhika
Pophale, Rupesh
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Ajani, J. A.
Lordick, F.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
Shah, M. A.
Van Cutsem, E.
Xu, R-H.
Aprile, G.
Xu, J.
Cid, R. A. Pazo
Kang, Y-K.
Yang, J.
Moran, D.
Bhattacharya, P.
Matsangou, M.
Arozullah, A.
Park, J. W.
Shitara, K.
ANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322
[8] First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW
Kang, Y-K.
Shah, M. A.
Shitara, K.
Ajani, J. A.
Lordick, F.
Van Cutsem, E.
Ilson, D. H.
Klempner, S. J.
Yamaguchi, K.
Nakajima, T.
Cao, Y. J.
Li, R.
Moran, D.
Pophale, R. R.
Ranganath, R.
Xu, R-H.
ANNALS OF ONCOLOGY, 2024, 35 : S895 - S895
[9] SPOTLIGHT: Comparison of zolbetuximab or placebo+mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Yamaguchi, K.
Shitara, K.
Al-Batran, S-E.
Bang, Y-J.
Catenacci, D.
Enzinger, P.
Ilson, D.
Kim, S.
Lordick, F.
Shah, M.
Van Cutsem, E.
Xu, R-H.
Arozullah, A.
Park, J. Wook
Ajani, J.
ANNALS OF ONCOLOGY, 2019, 30
[10] SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Lordick, F.
Shitara, K.
Al-Batran, S. -E
Bang, Y. -J
Catenacci, D.
Enzinger, P.
Ilson, D.
Kim, S.
Shah, M. A.
Van Cutsem, E.
Xu, R. -H
Arozullah, A.
Park, J. W.
Ajani, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218

← 1 2 3 4 5 →